Teva Pharmaceutical-sp Adr (TEVA) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

TEVA ranks #799 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

TEVA is a top-conviction position for Lingotto Investment Management LLP — at 14.7% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TEVA belongs to BlackRock, Inc., but the position matters far more to Lingotto Investment Management LLP, who has 14.7% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

IFP Advisors, Inc has added to its TEVA position for two straight quarters, increasing it by $1.0M to reach $5.3M today.

TEVA is up 1% today, and institutions have been net buyers of $3.3B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

TEVA posted net income of $706.0M over the trailing twelve months, and currently trades at a P/E of 67.7.

• Profitable — net income of $706.0M over the trailing twelve months
• Revenue grew 4.1% year over year
• Net income improved year over year, from -$158.0M to $706.0M
• Generated $1.6B in positive operating cash flow
• Current ratio of 1.04x — below the conventional 1.5x liquidity buffer
• Liabilities run 4.15x equity — a highly leveraged balance sheet worth noting